IGMS (IGM Biosciences) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences 3-Year Dividend Growth Rate?

IGM Biosciences's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The historical rank and industry rank for IGM Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:

IGMS's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 10.7
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

IGM Biosciences's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, IGM Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of IGM Biosciences's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, IGM Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGM Biosciences's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's 3-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

IGM Biosciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

IGM Biosciences (NAS:IGMS) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

IGM Biosciences's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.61
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGM Biosciences 3-Year Dividend Growth Rate Related Terms>

IGM Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

1K0:Germany

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Executives

Lisa Lynn Decker	officer: Chief Business Officer	C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Steven Weber	officer: Principal Accounting Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Misbah Tahir	officer: Chief Financial Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto	officer: Chief Medical Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Fred Schwarzer	director, officer: CEO and President	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt	officer: Chief Scientific Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
George Gauthier	officer: Chief Commercial Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z.	director	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jakob Haldor Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Christina Teng Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803